Novartis Malaysia’s rolls out two-dose per annum bad cholesterol treatment

INNOVATIVE healthcare solutions provider Novartis Malaysia has made available Sybrava – an effective and sustained treatment to gain control of low-density lipoprotein cholesterol (LDL-C).

Sybrava is an innovative therapy that aids in lowering LDL-C levels in the blood as an add-on to existing cholesterol-lowering treatments and lifestyle modifications. This therapy provides effective and sustained LDL-C reduction to improve patients’ health with only two maintenance doses a year.

Based on the results of ORION 10, a clinical study, the therapy provides an effective LDL-reduction of up to 52% in patients with elevated LDL-C despite already being on maximally tolerated cholesterol-lowering treatment.

“Sybrava helps medical professionals treat individuals who have high cholesterol despite treatment with maximally tolerated statins,” commented Novartis Malaysia’s country president Elwakil Mohamed.

“It offers a combination of a convenient twice-a-year maintenance dosing schedule as well as the ability to be used in primary care and provide sustained reductions in LDL-C is a hugely positive milestone in patient care.”

Added Elwakil: “We at Novartis Malaysia are committed to treating hypercholesteremia – or a high blood cholesterol level – with new innovative therapies.” – March 7, 2023

Subscribe and get top news delivered to your Inbox everyday for FREE